XORTX Therapeutics (XRTX) Share-based Compensation (IS) (2020 - 2026)
XORTX Therapeutics (XRTX) posted Share-based Compensation (IS) of $2,133 for the quarter ended Jun 30, 2026, down 69.3% from $6,945 a year earlier and down 72.7% from the prior quarter.
Powered by 
Analysis
XORTX Therapeutics (XRTX) Share-based Compensation (IS) (2020 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Share-based Compensation (IS) at XORTX Therapeutics was $19,190, down 53.5% year-over-year; for the year ended Dec 31, 2025, it was $18,004, down 79.9% from the prior year.
- Annual Share-based Compensation (IS) has declined for three consecutive years, with a five-year compound annual growth rate of -39.3% (years ended Dec 2020 to Dec 2025).
- In prior years, XORTX Therapeutics' Share-based Compensation (IS) was $89,494 in the year ended Dec 31, 2024 (-0.2%), $89,669 in the year ended Dec 31, 2023 (-81.6%), $487,940 in the year ended Dec 31, 2022 (+23.1%) and $396,423 in the year ended Dec 31, 2021 (+81.0%).
- The figure for the quarter ended Jun 30, 2026 stands as the lowest quarterly Share-based Compensation (IS) in data going back to the quarter ended Mar 31, 2020.
- On a year-over-year basis, Share-based Compensation (IS) has declined in each of the last eight quarters, with an average decline of 53.2% over the last eight quarters.
- The strongest year-over-year quarter for Share-based Compensation (IS) in the past five years was the quarter ended Jun 30, 2022, with growth of 188.7%; the weakest was the quarter ended Jun 30, 2023, with a decline of 91.2%.
- According to Business Quant data, Share-based Compensation (IS) for the three prior quarters was $7,816 (quarter ended Mar 31, 2026), $4,124 (quarter ended Dec 31, 2025) and $5,117 (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.26 Bn | 1,105.84 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 618.12 Bn | 536.65 Bn | 17.26 Bn | - |
| 3 | AbbVie | 503.25 Bn | 476.36 Bn | 12.70 Bn | - |
| 4 | Merck | 368.28 Bn | 322.66 Bn | 12.21 Bn | - |
| 5 | Novartis Ag | 298.45 Bn | 262.44 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.39 Bn | 235.08 Bn | 12.86 Bn | - |
| 7 | Amgen | 237.30 Bn | 192.70 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 191.35 Bn | 165.55 Bn | 6.22 Bn | - |
| 9 | Pfizer | 169.92 Bn | 116.56 Bn | 10.94 Bn | - |
| 10 | XORTX Therapeutics | 898,160.24 | -2.40 Mn | - | 2,133.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,133.00 |
| Mar 31, 2026 | 7,816.00 |
| Dec 31, 2025 | 4,124.00 |
| Sep 30, 2025 | 5,117.00 |
| Jun 30, 2025 | 6,945.00 |
| Mar 31, 2025 | 8,969.00 |
| Dec 31, 2024 | 9,505.00 |
| Sep 30, 2024 | 15,857.00 |
| Jun 30, 2024 | 44,031.00 |
| Dec 31, 2023 | 21,165.64 |
| Sep 30, 2023 | 16,298.58 |
| Jun 30, 2023 | 22,906.06 |
| Mar 31, 2023 | 39,550.00 |
| Sep 30, 2022 | 19,281.37 |
| Jun 30, 2022 | 333,311.84 |
| Mar 31, 2022 | 86,196.00 |
| Dec 31, 2021 | 113,840.55 |
| Sep 30, 2021 | 49,428.94 |
| Jun 30, 2021 | 90,451.00 |
| Mar 31, 2021 | 160,382.22 |
API Access
XORTX Therapeutics Share-based Compensation (IS) API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=share-based-compensation-is&ticker=XRTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "share-based-compensation-is", "ticker": "XRTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=share-based-compensation-is&ticker=XRTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();